This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSEA-TGT
an investigational sugar-engineered antibody directed to the immune checkpoint TIGIT
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGNTGT-001: Advanced solid tumors and lymphomas (SEA-TGT ± sasanlimab)
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of SEA-TGT and ongoing clinical trials

Detailed information about SEA-TGT clinical trials
Related Links